38results about How to "Improve oral glucose tolerance" patented technology

The invention relates to lactobacillus rhamnosus CCFM0528 having an inhibitory effect on alpha-glucosidase activity, the bacterial strain is preserved at the China General Microbiological Culture Collection Center (CGMCC), and the accession number is CGMCC No.7317. Cytoplasm and fermentation supernate of the CCFM0528 can respectively exhibit the inhibitory effects on the alpha-glucosidase activity, with the inhibition rates of 29.2% and 14.1% respectively. Studies show that the CCFM0528 exhibits the inhibitory effect not only on the alpha-glucosidase activity, also on glucose transport. The experimental results show that the CCFM0528 can prevent type-2 diabetes, effectively reduce fasting blood glucose and postprandial blood glucose of mice, and improve glucose tolerance of the mice. The principle may be that the CCFM0528 has inhibitory effect on the alpha-glucosidase activity and enzyme expression amount in intestinal tract, and can influence the gene expression level of glucose-transport relating protein SGLT-1 and GLUT-2.

The invention provides a diabetes-specific enteral nutrition multi-polymerization agent. The diabetes-specific enteral nutrition multi-polymerization agent comprises the following energy by weight percentage: 50%-60% of carbohydrates, 10%-15% of proteins and 25%-35% of fat, wherein the energy supply ratio of monounsaturated fatty acids is 10-20%. The invention provides the nutrition multi-polymerization agent with balanced nutrients and low GI (glycemic index) value against the metabolic characteristics of diabetic patients, which can effectively correct metabolic disorders, reduce the islet beta-cell load and delay and reduce the occurrence and development of diabetic complications. The diabetes-specific enteral nutrition multi-polymerization agent provided by the invention is particularly suitable for the diabetic patients, patients with severe symptoms, traumas and surgical stress associated with high blood sugar, and people with decreased sugar tolerance.

The invention relates to a mactra veneriformis extract which is prepared by the following method of taking the soft body part of the mactra veneriformis as a material, washing and grinding the material, adding water for decoction, filtering, then obtaining water decoction extracting solution, centrifuging the water decoction extracting solution,collecting supernatant fluid, concentrating, cooling, then adding ethanol for precipitating, filtering, obtaining an ethanol precipitate, drying and then obtaining the mactra veneriformis extract; and deproteinizing the mactra veneriformis extract to obtain purified mactra veneriformis extract which has glycemia-reducing, immune adjusting and liver-protecting functions. The invention also discloses the applications of the mactra veneriformis extract on preparation of medicaments or health care products simultaneously.

Provided is a strain CCFM8630 of Bifidobacterium adolescentis and use thereof. The strain CCFM8630 of Bifidobacterium adolescentis can significantly increase neurotransmitter 5-hydroxytryptamine level in peripheral blood of rat, recover the hormone levels, for example testosterone and so on in peripheral blood of rat, normalize abnormal abundances of Bifidobacterium genus, Blautia genus and Turicibacter genus in intestinal flora of rat affected by high-fat high-starch diet, show pretty good tolerance to simulated gastrointestinal fluid and quickly colonize in intestinal, significantly improve pathological damages of tissues such as liver, duodenum and so on, and increase triglyceride and total cholesterol levels in serum and oral glucose tolerance of rat with metabolic syndrome caused by high-fat high-starch diet. The strain CCFM8630 of Bifidobacterium adolescentis can be used for preventing, relieving or treating metabolic disorder, such as metabolic syndrome, irritable bowel syndrome and mental diseases related to metabolic syndrome such as anxiety, depression and so on.

The invention discloses application of bifidobacterium adolescentis CCFM1061 in preparation of functional microbial agents, foods and/or medicines. The bifidobacterium adolescentis CCFM1061 can be rapidly colonized in the intestinal tracts, can remarkably improve fasting blood glucose and oral glucose tolerance of type 2 diabetes induced by STZ and high-fat diet and decrease the area under a curvewhen glucose tolerance is reduced, can remarkably alleviate the increase of total cholesterol and the decrease of high-density lipoprotein cholesterol in serum of the type 2 diabetes caused by STZ and high-fat diet, can remarkably alleviate the insulin resistance of the type 2 diabetes, can remarkably improve the level of inflammation in liver tissues of the type 2 diabetes, and can remarkably alleviate the pathological damage of the pancreas, liver and other tissues of the type 2 diabetes. In addition, the bifidobacterium adolescentis CCFM1061 has strong adsorption capacity on perfluorooctanoic acid (PFOA), and has the capacity of relieving PFOA toxicity.

The invention relates to a novel nitrogen-containing heterocyclic derivative shown as a general formula (I) (please see the formula in the description) and a preparation method thereof and application of a pharmaceutical composition containing the derivative in preparation of a drug for treating diabetes and a metabolic syndrome. The nitrogen-containing heterocyclic derivative has the excellent in-vivo hypoglycemic activity and can be used for preventing or treating the diabetes.

The invention relates to uses of compounds shown as a general formula I, stereisomers thereof or medicinal salts of the compounds in preparation of medicines used for treating diabetes mellitus, or in preparation of medicines for preventing or treating diabetic complications, or in preparation of medicines adopted as euglycemic agents.

The invention relates to a ginsenoside Rb3 composition and an application thereof in preparing a medicament for treating diabetes. The ginsenoside Rb3 composition is prepared from ginsenoside Rb3 as a main component and 1-5 of a carrier, an excipient, a sweetening agent, an adhesive, a flavoring agent, a preservative, a dispersing agent, a surfactant and a colorant as adjuvants, and the medicament is prepared into tablets, pills, granules, capsules and powder. The method for extracting the ginsenoside Rb3 comprises the following steps: dissolving crude extracts of stems and leaves of American ginseng, ginseng or pseudo-ginseng in water, then separating by NKA-12 macroporous resin, and performing gradient elution by ethanol water to obtain panaxatriol saponin and panaxadiol saponin. Repeated chromatography is preformed on the panaxadiol saponin by silicagel columns to obtain pure ginsenoside Rb3 with the purity of 98%. Proven by animal experiments, the ginsenoside Rb3 has notable effects of symptom improvement and treatment on diabetes and adiposis.

The invention belongs to the field of medicines and health-care products, and particularly discloses composite polysaccharide, a preparation method thereof and application thereof to products for clearing damp, tonifying spleen, reducing fat and losing weight. The composite polysaccharide is prepared from mangnolia officinalis, rhizoma atractylodis macrocephalae, dried orange peel, cortex lycii radicis and black mulberry. The preparation method of the composite polysaccharide comprises water extraction and alcohol precipitation. The composite polysaccharide provided by the invention can obviously reduce body mass increasing rate of a nutritional obesity rat model and retard increment of body weight and Lee's index, can reduce fat mass, fat body ratio and fat cell number, reduce accumulation of internal fat, reduce triglyceride and total cholesterol, adjust high-density lipoprotein and high-density lipoprotein, improve hyperlipidemia, reduce fasting blood glucose, improve oral glucose tolerance and improve the appearance condition and the mental outlook of the nutritional obesity rat, has the effect which is obviously excellent than that of each single polysaccharide component, andcan be used for preparing the medicines or health-care food with effects of clearing damp, tonifying spleen, reducing fat and losing weight.

The invention provides floccularia luteovirens polysaccharide as well as a preparation method thereof and a medical use thereof in controlling diabetes. Crude polysaccharide obtained by water extraction and alcohol precipitation of floccularia luteovirens is subjected to protein removal to obtain any one or more of floccularia luteovirens total sugar, floccularia luteovirens protein composite, floccularia luteovirens polysaccharide or purified homogeneous polysaccharide component. According to the animal experiment, the floccularia luteovirens polysaccharide can reduce bodyweight growth speedof a db/db mouse, reduces fasting blood-glucose of a diabetic mouse, improves oral glucose tolerance, and has good activity of reducing blood fat, resisting oxidization and resisting inflammation. Thefloccularia luteovirens polysaccharide is taken as a natural product obtained from an edible and medicinal fungus resource, is small in toxic and side effect, has remarkable effects of resisting oxidative stress and inflammation, realizing the effects of resisting type 2 diabetes and renal complications, further can be used for developing medicines and healthcare products for safely and effectively preventing, alleviating or treating type 2 diabetes and renal complications caused by diabetes, and has an extremely high edible value, an extremely high medical value and an extremely high economical value.

The present invention relates to a novel phenoxyacetic acid derivative represented by the general formula (I), preparation method thereof and use of a pharmaceutical composition containing the derivative in preparing a medicament for treating diabetes and metabolic syndrome. The phenoxyacetic acid derivatives have excellent in vivo hypoglycemic activity, which can be used for preventing or treating diabetes.

The present invention discloses an application of narrow-range chitosan oligosaccharide in a preparation of functional food for preventing hyperglycemia induced by a long-term high-fat diet. Functionsof the narrow-range chitosan oligosaccharide for preventing the hyperglycemia manifest as a reduction of fasting blood glucose. At the same time, the narrow-range chitosan oligosaccharide also improves oral glucose resistance and insulin resistance induced by the high-fat diet, increases insulin secretion and insulin sensitivity, reduces insulin resistance indexes, alleviates liver tissue fatty degeneration, and restores pancreatic tissue structures. Due to the fact that the used chitosan oligosaccharide is relatively concentrated in molecular weight distribution, a mechanism of a hypoglycemic effect is clearer. By improving excessive gluconeogenesis caused by the high-fat diet, the narrow-range chitosan oligosaccharide promotes glucose transport in muscle tissues and thereby exerts hypoglycemic effects. The used narrow-range chitosan oligosaccharide is developed into the functional food for assisting sugar-lowering and at the same time also provides strong research foundation for theapplication of the chitosan oligosaccharide in assisting the sugar-lowering.

The invention discloses tuna roe dipeptidyl peptidase IV (DPP-IV) inhibition oligopeptide and application thereof. The amino acid sequence of the DPP-IV inhibition oligopeptide is Glu-Ile-Pro-Gly-Thr-Arg-Gly-Pro-Leu, and the molecular weight of the DPP-IV inhibition oligopeptide is 939.07 Da. The prepared tuna roe DPP-IV inhibition oligopeptide can significantly inhibit the activity of DPP-IV, reduce the postprandial blood sugar level of a model mouse, improve the oral glucose tolerance and maltose tolerance of the mouse and reduce the content of triglyceride (TG) and cholesterol (TC) of the model mouse, and is safe and free of toxic and side effects; and the tuna roe DPP-IV inhibition oligopeptide can be applied to preparation of food, health-care products and medicines with special medical purposes for treatment or adjuvant treatment of diabetes mellitus type 2 (T2DM).

The invention relates to a preparation method of berberine derivative-alcohol form berberine which includes the following steps: the raw materials of berberine hydrogen sulfate are dissolved in water to prepare the saturated solution of berberine hydrogen sulfate; alkaline solution is dropped in the saturated solution of berberine hydrogen sulfate till no generation of the sediment so as to form the turbid solution; the turbid solution is filtered to get the sediments; all the sediments are dissolved in the organic solvent and are carried out the silica gel column chromatography and elution by organic solvent; the crude product can be obtained by concentration under the reduced pressure of the organic solvent elution solution and vacuum low-temperature drying; the obtained crude product is carried out the recrystallization by using methanol or ethanol so as to get enough amount of berberine derivative pure product. The animal experiments find that the prepared berberine derivative has a variety of pharmaceutical activities and shows the great function of regulating the blood glucose and blood lipids of the rats with the type 2 diabetes, compared with the currently recognized berberine hydrochloride compounds which have the function of regulating the blood glucose and blood lipids and the most relevant structure, the efficacy is much better and the effective dose is much less.